세계의 기면증 치료제 시장 규모, 점유율, 성장 분석, 질병 유형별, 치료제 유형별, 지역별 시장 규모, 점유율, 성장 분석 - 산업 예측(2024-2031년)

Global Narcolepsy Drugs Market size was valued at around USD 3.4 billion in 2022 and is expected to rise from USD 3.7 billion in 2023 to reach a value of USD 7 billion by 2031, at a CAGR of 9.5% over the forecast period (2024-2031).

The narcolepsy therapeutics market is poised for substantial growth driven by several key factors, primarily the aging population's increased susceptibility to chronic and acute ailments necessitating medical care. The rise in narcoleptic disorders, exacerbated by evolving lifestyles and heightened stress levels, is expected to further fuel market expansion in the coming years. Enhanced research initiatives, increased healthcare spending, and improved medical infrastructure underscore this growth potential. Additionally, factors such as circadian adjustment, increased sleep, and telework practices suggest that symptoms associated with central hypersomnia can be effectively managed, encouraging a broader acceptance of narcolepsy treatments. However, challenges exist, notably the high costs associated with treatments and diagnostics, coupled with an overarching lack of awareness regarding available therapies, which are likely to hinder market progress. The unfavorable reimbursement landscape also poses significant obstacles, potentially impacting revenue opportunities for pharmaceutical companies focused on targeted research and development. Despite these challenges, the US narcolepsy drugs market is expected to experience a steady compound annual growth rate (CAGR) over the next forecast period, reflecting a resilient demand for treatments amid an evolving healthcare landscape that increasingly prioritizes sleep-related disorders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Narcolepsy Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Narcolepsy Drugs Market Segmental Analysis

Global Narcolepsy Drugs Market is segmented by Disease Type, Therapeutics Type, and region. Based on Disease Type, the market is segmented into Daytime Extreme Sleepiness, Cataplexia, and Other Disease Type. Based on Therapeutics Type, the market is segmented into Central Nervous System Stimulants, Tricyclic Antidepressants, Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, and Other Therapeutic Type. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Narcolepsy Drugs Market

Growing awareness surrounding narcolepsy treatment plays a crucial role in driving the Global Narcolepsy Drugs market from 2023 to 2030. As more patients and healthcare providers recognize the impact of the condition on quality of life, the demand for effective treatments is surging. Notably, the preference for modafinil, which is known for its favorable safety profile compared to traditional stimulants, is further contributing to this trend. This increased focus on appropriate therapeutic options not only enhances patient outcomes but also fosters market growth, as effective therapies become more widely adopted, driving sales and innovation within the narcolepsy drug sector.

Restraints in the Global Narcolepsy Drugs Market

A significant market restraint for the global narcolepsy drugs market is the frequent misdiagnosis of narcolepsy symptoms, which are often confused with various mental and neurological disorders. This lack of awareness leads to inappropriate prescriptions of antiepileptics and psychiatric medications, particularly in children and adolescents, potentially causing adverse health effects. The resulting hesitation from healthcare providers to accurately diagnose and treat narcolepsy can hinder market growth, as patients may not receive the necessary therapy for their condition. Additionally, this confusion can create mistrust among patients towards seeking effective treatments, further limiting market opportunities for narcolepsy drug manufacturers.

Market Trends of the Global Narcolepsy Drugs Market

The global narcolepsy drugs market is poised for significant growth, fueled by the rising prevalence of narcolepsy and associated sleep disorders across diverse demographics. Increasing incidences of obesity-related narcolepsy variants further bolster market expansion, highlighting the pressing need for effective therapeutic solutions. Government initiatives aimed at enhancing awareness and understanding of narcolepsy are anticipated to drive demand for treatment options. Moreover, hospitals are emerging as the primary end-use sector, capturing the largest share of the market as more patients seek specialized care. Overall, this confluence of factors positions the narcolepsy drugs market for robust growth in the coming years.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Regulatory Analysis
• Case Study Analysis
• Clinical Trials

Narcolepsy Drugs Market, By Disease Type

• Market Overview
• Daytime Extreme Sleepiness
• Cataplexia
• Other Disease Type

Narcolepsy Drugs Market, By Therapeutics Type

• Market Overview
• Central Nervous System Stimulants
• Tricyclic Antidepressants
• Sodium Oxybate
• Selective Serotonin Reuptake Inhibitor
• Other Therapeutic Type

Narcolepsy Drugs Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Jazz Pharmaceuticals plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioprojet Pharma SARL
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis International AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avadel Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (now part of Viatris)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Glenmark Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Theravance Biopharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ligand Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Flamel Technologies (now Avadel Pharmaceuticals)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocodex
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments